|  |  | 2004 |  |  |  | 2007 |  | |
---|---|---|---|---|---|---|---|---|---|
 | Research Industry | Generic Industry | Civil Society | Government | IPIC | Research Industry | Generic Industry | Civil Society | Government |
 | (n = 3622) | (n = 2938) | (n = 31610) | (n = 19956) | (n = 3327) | (n = 8785) | (n = 4146) | (n = 14327) | (n = 11330) |
Equity | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Aid | 41% | 25% | 17% | 13% | 0% | 29% | 12% | 25% | 29% |
List of Countries | 1% | 0% | 7% | 11% | 0% | 0% | 0% | 0% | 6% |
List of Medicines | 0% | 4% | 12% | 18% | 0% | 3% | 2% | 8% | 3% |
Equal Opportunity to supply | 22% | 1% | 2% | 0% | 0% | 0% | 0% | 1% | 0% |
Security | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Drug Affordability | 12% | 19% | 15% | 2% | 19% | 17% | 21% | 17% | 7% |
Development | 8% | 0% | 17% | 5% | 0% | 19% | 2% | 11% | 12% |
Domestic Economy | 0% | 4% | 0% | 0% | 0% | 1% | 4% | 0% | 0% |
Human Rights | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 1% | 1% |
Innovation | 2% | 1% | 2% | 4% | 0% | 2% | 5% | 2% | 1% |
Quality and Safety | 3% | 9% | 1% | 5% | 4% | 2% | 4% | 3% | 10% |
Neglected Diseases | Â | Â | Â | Â | Â | 0% | 0% | 1% | 0% |
Liberty | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Intellectual Property | 23% | 44% | 25% | 41% | 63% | 34% | 43% | 23% | 37% |
Developing Country Pressure | 0% | 0% | 2% | 0% | 0% | 0% | 4% | 5% | 0% |
Right of Refusal | 10% | 8% | 16% | 7% | 18% | 0% | 0% | 0% | 0% |
WTO or TRIPS | 21% | 13% | 27% | 22% | 11% | 12% | 7% | 23% | 21% |
Efficiency | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Diversion | 13% | 0% | 2% | 10% | 9% | 5% | 3% | 2% | 2% |
Litigation | 0% | 0% | 0% | 7% | 6% | 0% | 1% | 4% | 3% |
Market Competition | 4% | 13% | 11% | 1% | 11% | 1% | 11% | 4% | 1% |
Procurement | 15% | 6% | 4% | 2% | 5% | 5% | 3% | 10% | 3% |
Profit and ROI | 3% | 7% | 4% | 6% | 4% | 4% | 6% | 3% | 3% |
Eligible Importers | 0% | 14% | 6% | 3% | 0% | 0% | 0% | 1% | 0% |
CAMR Outcomes and Uptake | 0% | 0% | 0% | 0% | 0% | 18% | 13% | 14% | 24% |